Business
HLS Therapeutics Announces Q2 2025 Financial Results
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and six months ended June 30, 2025 ("Q2 2025" and "year-to-date"). All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.
About this update from Esperion Therapeutics, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Adjusted EBITDA grew 21% in Q2 and 29% year-to-date ","length":51,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash from operations grew 83% in Q2 and 147% year-to-date","length":57,"tagName":"p"}]},{"val":[{"type":"text","content":"Made principal repayments on the Company's long-term debt totalling $8.5 million","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanded cardiovascular portfolio by licensing Canadian rights to NEXLETOL® and NEXLIZET® from Esperion Therapeutics","length":116,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":308,"olType":false},{"type":"text","content":"TORONTO, Aug. 14, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and six months ended June 30, 2025 ("Q2 2025" and "year-to-date"). All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.","length":474,"tagName":"p"},{"type":"text","content":"Q2 & YEAR-TO-DATE 2025 FINANCIAL HIGHLIGHTS (comparisons are to the respective 2024 periods)","length":96,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Q2 2025 revenue was $14.2 million, Adjusted EBITDA1 was $5.2 million and cash from operations was $4.6 million, compared to $14.5 million, $4.3 million and $2.5 million, respectively.","length":183,"tagName":"p"}]},{"val":[{"type":"text","content":"Year-to-date 2025 revenue was $26.8 million, Adjusted EBITDA was $9.0 million and cash from operations was $8.1 million, compared to $27 million, $7 million and $3.3 million, respectively.","length":188,"tagName":"p"}]},{"val":[{"type":"text","content":"In local currency, combined Canadian product sales for Vascepa and Clozaril were flat in Q2 2025 and were up 6% year-to-date.","length":125,"tagName":"p"}]},{"val":[{"type":"text","content":"US sales of Clozaril were up 1% in Q2 2025 and were up 2% year-to-date.","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"Excluding cost of sales, operating expenses decreased 18% in Q2 2025 and 19% year-to-date.","length":90,"tagName":"p"}]},{"val":[{"type":"text","content":"Vascepa made ...